Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?
Hope E Uronis and Herbert I Hurwitz*
Correspondence *Department of Medicine, Division of Medical Oncology, Room 3802 Red Zone, Duke South Clinics, Duke University Medical Center, Box 3052, Durham, NC 27710, USA
Email hurwi004@mc.duke.edu
This article has no abstract so we have provided the first paragraph of the full text.
In the current report, Giantonio et al. present the results of a phase II study demonstrating that treatment with first-line weekly bolus IFL plus bevacizumab (5 mg/kg/week) is safe in patients with metastatic colorectal cancer and results in a PFS of 10.7 months. Of note, the 49.4% RR and 10.7-month mean PFS reported in this trial are very similar to the 44.8% RR and 10.3-month mean PFS seen in a randomized phase III trial that compared IFL with IFL plus bevacizumab (2.5 mg/kg/week).1 The toxicity seen in the current study is also consistent with that seen in the phase III study.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.